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Background. EPC number and functionality are assumed to reflect the endogenous vascular repair capacity with the EPC pool
declining in higher ages and being exhausted by unfavorable life-style and risk factors. This intriguing and clinically highly
relevant concept, however, has so far been derived from small case-control studies and patient series. Methodology and
Principle Findings. In the population-based Bruneck Study EPC number and EPC-colony forming units (EPC-CFU) were
assessed as part of the fourth follow-up evaluation (2005) in 571 and 542 subjects, respectively. EPC number declined with age
(p=0.013), was significantly lower in women (p=0.006) and higher in subjects on statin, hormone replacement or ACE
inhibitor/angiotensin-receptor blockers, and correlated positively with moderate alcohol consumption. Unexpectedly,
a positive relation between EPC number and several vascular risk factors emerged. In a step forward multivariate linear
regression analysis EPC number was independently related with SDF1a, MMP-9, triglycerides, alcohol consumption, and Hba1c.
EPC-CFU in turn was related to SDF1a and diastolic blood pressure. Moreover, EPC number showed a significant positive
association with the Framingham risk score (P=0.001). Finally, there was an inverse association between EPC number and
common carotid artery intima-media thickness (p=0.02) and the carotid artery atherosclerosis score (p=0.059). Conclusions.
Our population-based data confirm the decline of EPC number with advancing age and lend first epidemiological support to
a role of SDF-1a and MMP9 in EPC differentiation, mobilization and homing, but are conflict with the view that EPC number is
unfavorably affected by cardiovascular risk factors. EPC number increases with the cardiovascular risk estimated by the
Framingham risk score (FRS), which in the absence of similar changes for EPC-CFU. Finally, we demonstrate a significant inverse
association between EPC number and extent of carotid atherosclerosis even though this association was only of moderate
strength and not entirely consistent in other vascular territories.
Citation: Xiao Q, Kiechl S, Patel S, Oberhollenzer F, Weger S, et al (2007) Endothelial Progenitor Cells, Cardiovascular Risk Factors, Cytokine Levels and
Atherosclerosis – Results from a Large Population-Based Study. PLoS ONE 2(10): e975. doi:10.1371/journal.pone.0000975
INTRODUCTION
Asahara and colleagues first isolated circulating angioblasts from
human peripheral blood, which had the potential to differentiate
in vitro into endothelial cells and to contribute to neoangiogenesis
after tissue ischemia in vivo, and defined this cell population as
endothelial progenitor cells (EPC)[1,2]. The mostly used methods
to define EPC are the identification of mononuclear cell
population expressing CD34, KDR/VEGFR2, and CD133/
AC133 with adherent growth characteristics, whereas the function
and the clonogenic capacity of EPC are evaluated using colony-
forming units (EPC-CFU) assays[3,4].
Functionally, it is believed that EPC play an important role in
regeneration of ischemic and damaged tissues via angiogenesis and
repairing denuded endothelium in the injured vessels[5–7]. It was
demonstrated that reduced numbers of EPC predict future
cardiovascular events and proposed that low EPC number and
EPC-CFU reflect an impaired endogenous repair capacity[8,9].
Of particular note, circulating EPC are believed to be depleted by
standard cardiovascular risk factors and unfavorable life-style, and
concerns have been expressed that this may restrict the therapeutic
potential of progenitor cells[10]. Actually, several case-control
studies and evaluations in patient series have demonstrated inverse
associations between EPC number and age[11], diabetes[12],
smoking[13], hypertension[14], family history for coronary artery
disease[12], CRP leve[15], physical inactivity[16] and the
Framingham risk score[4]. Evidence, however, is far from
consistent with several studies failing to obtain such relations
(especially after controlling for age) and some even reporting the
opposite. For example, two recent studies including the largest
available obtained a significant positive association between EPC
number and smoking[8] or some risk factors in baseline level, such
as arterial hypertension, hyperlipidemia, diabetes, family history of
coronary artery diseases (CAD), and bod-mass index[9]. Further-
more, there is still a disturbing lack of in-depth insights into the
mechanisms controlling EPC mobilization and turn over in
humans. Further experimental and epidemiological studies are
required to resolve all the controversies surrounding this intriguing
issue. The current study is the first large scale evaluation in the
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of EPC number and EPC-CFU with cardiovascular risk factors
and life-style behaviors. An additional focus will be on the
potential relation of EPC characteristics with atherosclerosis as
well as levels of cytokines and growth factors previously implicated
in EPC differentiation[17], mobilization[18,19] and homing[20,21].
METHODS
Study Population
Population recruitment was performed as part of the Bruneck
Study[22]. The survey area was located in the north of Italy
(Bolzano Province). Special features of the study design and
protocol have been described previously in detail[22]. The current
study focused on the follow-up in 2005. EPC number and EPC-
CFU were assessed in 571 and 542 of the 574 participants.
Subjects with and without EPC number and EPC-CFU assess-
ments did not differ in age, sex and expression of cardiovascular
risk factors. The appropriate ethics committees (Autonome
Provinz Bozen-Sanitatsbetrieb Bozen Ethikkomittee) approved
the study protocol and all study subjects gave their written
informed consent before entering the study.
EPC Culture assay (EPC number)
PBMNC isolation from Venous blood and EPC identification
were performed as previously reported[23–27]. Double positive
stained cells for DiI-Ac-LDL and Lectin were considered as EPC
on day 5 of culture. The total numbers of EPC per well were
counted by two trained independent senior investigators blinded to
the clinical details of the subjects. The EPC in a minimum of two
wells were counted and the average was then recorded. Re-
producibility was assessed over 50 samples in the present study by
comparing the EPC numbers from the two individuals. Coefficient
of variance was ,10% in each case.
EPC-CFU assay
The EPC-CFU assay performed as described previously[4,12,28].
PBMNC were resuspended in EPC culture medium (M199 with
20%FCS and antibiotics) and then plated on fibronectin coated 6
well plates at a concentration of 5 million cells per well. The
endothelial colonies were counted manually on day 7. Strict
guidelines were followed to ensure consistent counting of EPC
colonies. Two senior investigators who were blinded to the
subjects’ clinical status counted colonies. Reproducibility was
assessed over 50 samples in the present study comparing colony
counts by the two individuals. Coefficient of variance was ,10%
in each case.
Reproducibility assay
To assess reproducibility, the cEPC and EPC-CFU numbers were
determined twice in two separate blood samples obtained at least
one week apart from 10 subjects in our preliminary experiment.
The samples were analyzed independently by two observers who
were blinded to subjects’ clinical profiles. The interobserver
correlations were 0.965 and 0.975 for cEPC and EPC-CFU assay,
whereas the intraclass correlations obtained from a single observer
who analyzed two blood samples collected at least one week apart
from 10 subjects, were 0.939 and 0.961, respectively.
Enzyme-linked immunosorbent assay (ELISA)
Plasma granulocyte-colony stimulating factor (G-CSF), stromal
cell-derived factor-1a (SDF1-a), vascular endothelial growth factor
(VEGF) and matrix metalloproteinase-9 (MMP-9) levels were
determined using commercially available kits (Quantikine, R&D
Systems, UK). All ELISA tests were carried out at room
temperature on freshly thawed plasma samples. The concentration
of all cytokines was determined by comparison with a standard
curve, following manufacturer’s instruction. Other laboratory
parameters were all examined by standard methods[29].
Scanning Protocol and definition of Ultrasound End
Points
The ultrasound protocol involves the scanning of the internal
(bulbous and distal segments) and common carotid arteries
(proximal and distal segments) of either side with a 10-MHz
imaging probe[30]. The intima-media thickness (IMT) was
quantified at the far wall of plaque-free sections of the common
carotid arteries as the distance between the lumen-intima and
media-adventitia interface (intra-observer coefficient of variation,
7.9 percent (n=100))[30].
Statistical Analysis
The data were analyzed using the SPSS 12.0 and BMDP software
packages. Levels of variables according to tertile groups for EPC
number and EPC-CFU were presented as mean values6SD or as
medians with corresponding 25th and 75th percentiles (continuous
variables), and as absolute numbers and percentages (dichotomous
variables). Associations of EPC number and EPC-CFU tertile
groups with vascular risk factors, life-style and demographic
variables, IMT and severity of atherosclerosis were assessed using
generalized linear models and logistic regression analysis. We
performed tests for linear trend by treating the medians in each
category of EPC number and EPC-CFU as a continuous variable.
Levels of C-reactive protein, lipoprotein (a), D-dimer, triglycerides
and urinary ACR were loge-transformed to satisfy the assumption
of normality and constant variance of the residuals. The
association between EPC number and EPC-CFU and IMT and
the carotid atherosclerosis score was tested by means of linear
regression analysis. The multivariate models included the variables
age (years), sex (female, male), smoking (number of cigarettes
smoked daily), alcohol consumption (g/day), diabetes (no, yes),
body mass index (kg/m
2), HDL and LDL cholesterol (mg/dL),
loge-transformed triglycerides (mg/dL), loge-transformed hs-CRP
level (mg/L), loge-transformed Lp(a) level (mg/dL), loge-trans-
formed urinary ACR (ratio), ferritin concentration (mg/L), systolic
blood pressure (mmHg) and facultatively various types of
medication. A two-sided p value ,0.05 was considered significant.
RESULTS
Measurement and distribution of EPC and EPC
colony
Detailed Characterization of EPC in colony formation and
quantification assay was carried out in present study (Text S1
and figure S1). The EPC number in circulation was investigated
in all the 571 subjects, but only 542 subjects were subject to EPC
colony analysis due to the limitation of blood sample and PBMNC
number in 29 subjects. In this study, we have determined the EPC
number and EPC-CFU number by adjusting to per 10
6 PBMC
and per 1 ml of blood, to avoid any discrepancy caused by total
circulating PBMNC variation happened in some situation. The
later data (per 1 ml of blood) are summarized in the online
supplementary data, which are very similar for most aspects to
former data (per 10
6 PBMC) (Data not shown).F igure S2A
show the non-normal distribution of EPC number and EPC-CFU
number (per 10
6 PBMC), which indicate that the EPC and EPC-
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into (0-1000 EPC) and (0-250 EPC-CFU) score groups, re-
spectively. Figure S2B illustrates a moderate but significant
decline of EPC number (P=0.013) but not EPC-CFU number
(per 10
6 PBMC) with age.
Associations of EPC and EPC-CFU number with
cardiovascular risk factors and other variables
Table 1 described the associations of demographic and life-style
characteristics, vascular risk factors, laboratory parameters and
medications with EPC number in circulation. EPC number was
significantly lower in female subjects (p=0.006). It can be clearly
seen that there was no inverse correlation between levels of various
risk factors and EPC number. On the contrary, some risk factors
showed positive correlations, for instance hypertension (p=0.009),
Hba1c level (p=0.016) and triglycerides (p=0.001). The positive
correlations between EPC number and hypertension, Hba1c and
triglycerides remain significant even when restricting the analyses
to subjects without any medication, which indicates that these
unexpected trends are not confounded by drug therapy. In
addition, there is a positive correlation with alcohol consumption
(p=0.014) and with some types of medications (statins, hormone
replacement and ACE inhibitors/angiotensin-receptor blockers).
However, no clear correlation between EPC number and cardio-
vascular disease history was found. Table 2 describes the
associations of demographic and life-style characteristics, vascular
risk factors, laboratory parameters and medications with EPC-CFU
number. There was no clear correlation observed between EPC-
CFU number and levels of risk factors or other variables except for
a weak correlation with diastolic blood pressure (p=0.017).
The EPC numbers, but not EPC-CFU, are positively
correlated with the FRS
Figure 1A shows the association between EPC number and the
FRS (10-years risk). Surprisingly, a positive association between
EPC number and the FRS emerged (P=0.001). There was no
differential association in men and women and significance was
maintained when adjusting for the use of statins, hormone
replacement therapy, ACE inhibitors and angiotensin receptor
blockers all of which may affect levels of circulating EPC.
However, we did not find any association between EPC-CFU
number and the FRS (data not shown).
Inverse correlation of EPC but not EPC-CFU with
common carotid artery atherosclerosis
Table S1 and Figure 1B illustrated the associations of EPC and
EPC-CFU number with common carotid artery intima-media
thickness (CCA IMT) and the carotid artery atherosclerosis score.
EPC number but not EPC-CFU were inversely associated with
CCA IMT (p=0.02) and the atherosclerosis score (P=0.059). In
the femoral arteries, however, inverse trends of association
between EPC number and both IMT and the atherosclerosis
score clearly fell short of statistical significance.
The strongest determinant of EPC and EPC-CFU
number and function is the SDF-1a level
Table 3 and 4 show the associations of progenitor related
cytokines with EPC number and EPC-CFU number. It is apparent
that plasma SDF-1a levels were significantly and inversely related
to EPC number (p=0.02) and EPC-CFU number (p=0.013).
However, there are no significant correlations between EPC or
EPC-CFU number and VEGF, MMP-9, and G-CSF levels in the
univariate analysis. In a step forward multivariate linear regression
analysis allowing for all variables in Tables 1 and 4, loge-
transformed EPC number was independently related with loge-
transformed SDF-1a (inverse relation, P,0.001), loge-transformed
MMP-9 (P=0.005), loge-transformed triglycerides (P=0.009),
alcohol consumption (P=0.002) and Hba1c (P=0.052). Loge-
transformed EPC-CFU number in turn was related to loge-
transformed SDF-1a and diastolic blood pressure (both inverse,
P=0.001 and P=0.007).
DISCUSSION
Our study lends further support to the previous observations that
EPC number declines with advancing age and is influenced by
standard cardiovascular drugs, refutes the concept that the
circulating EPC pool is exhausted and repair capacity impaired
by vascular risk factors and an unfavorable life-style and reports
important novel findings like the significant association between
EPC number and cytokine levels as well as carotid artery IMT.
Most important consideration in EPC experiment is the
methods to choice. Various surface markers are expressed on
EPCs and are used for EPC characterization[3], for example
CD34, vascular endothelial growth factor receptor 2 (VEGFR2) or
kinase domain receptor (KDR). Further studies indicated that
there is an immature subset of EPCs which expresses the surface
marker AC133 or CD133 and share more characteristics of stem/
progenitor cells[3,31,32]. The ability of peripheral blood-derived
EPCs to form ‘‘late-outgrowth colony-forming units–ECs’’ under-
lines their stem cell–like properties and gives information about
the clonogenic potential of these cells. This cell heterogeneity may
apparently reflect different developmental stages of EPCs during
the maturational process from the bone marrow residual cell to the
mature vascular wall cell. So far, the most used methods to define
EPCs are identifying mononuclear cell population expressing
CD34, KDR/VEGFR2, and CD133/AC133 with adherent
growth characteristics, and measuring the circulating numbers of
EPCs by flow cytometry using either antibodies against CD34 and
KDR or CD133. Whereas the function and the clonogenic
capacity of EPC should be evaluated using colony-forming unit
(EPC-CFUs) assays[3,4]. The methods to measure the circulating
numbers of EPCs by flow cytometry using either antibodies against
CD34 and KDR or CD133 were used in many previous studies.
However, very strict and rigorous technology in flow cytometry
analysis is needed and a completed negative/positive control
should be included in this analysis, because it is very difficult to
reproduce the data of EPC numbers due to the limitation of non-
specific background of this measurement and just a very small
fraction of EPCs existed in the circulation. Alternatively,
phenotypes of human EPCs may be confirmed by uptake of 1,
19-dioctadecyl-3, 39 39-tetramethylindo-carbocyanine-labeled ace-
tyl low-density lipoprotein (DiI-Ac-LDL) and binding of ulex-
lectin[33]. Many important studies have shown that EPCs could
be characterized and identified by dual-staining for DiI-Ac-LDL,
lectin, and expression of endothelial markers KDR, VE-cadherin,
and vWF[23,25–27]. According to our preliminary data and
previous publications[23–27], double positive cells for DiI-Ac-
LDL and Lectin were counted as cEPCs and used in the present
study to analyze the EPC numbers in circulation.
Obviously, our findings are different compared to the other
published clinical studies in cardiovascular disease. As mentioned
above, such discrepancy may be due to different methods used to
characterise and quantify putative EPCs, preventing straightfor-
ward comparisons between them and probably explaining the
difference in the results. The methods to measure the circulating
EPC in a General Population
PLoS ONE | www.plosone.org 3 October 2007 | Issue 10 | e975Table 1. Association of demographic and life-style characteristics, vascular risk factors, laboratory parameters and medication with
EPC number (n=571)
..................................................................................................................................................
CHARACTERISTIC* TERTILE GROUP FOR EPC NUMBER P Value for Trend
{
Low EPC level (n=190) Medium EPC level (n=190) High EPC level (n=191)
EPC number (per 10
6 PBMNC)
Median 127 560 1386
Range 17–295 296–859 860–4768
Demographic variables
Age (years) 71.2610.2 67.569.2 68.968.9 0.072
Sex (%) 0.006
Men 40.0 45.3 53.9
Women 60.0 54.7 46.1
Life-style and vascular risk variables
Smoking (%) 14.7 11.1 15.2 0.995
Smoking (cigarettes per day) 1.564.3 1.364.3 1.965.4 0.646
Alcohol consumption (g/day) 13.5620.6 18.2626.8 22.6627.9 0.014
Physical activity (Sports score) 2.360.7 2.460.7 2.460.7 0.892
Diabetes mellitus (%) 10.5 6.8 13.6 0.109
Fasting glucose (mg/dL) 102.1625.0 100.2614.1 106.2625.7 0.050
Hba1c (%) 5.760.7 5.660.4 5.960.8 0.016
Waist (cm) 90.8612.2 90.9612.6 92.2611.8 0.727
Body-mass index (kg/m
2) 25.964.2 25.964.2 26.164.1 0.715
HDL cholestrerol (mg/dL) 62.3613.5 67.2614.3 62.8613.8 0.639
LDL cholestrerol (mg/dL) 134.0631.4 140.9633.3 132.5637.4 0.705
Triglycerides (mg/dL) 112 (91–151) 114 (91–152) 124 (92–181) 0.001
Lipoprotein(a) (mg/dL) 15.1 (5.4–37.1) 14.4 (6.4–46.9) 12.9 (4.8–40.9) 0.810
High-sensitivity CRP (mg/L) 2.1 (1.0–4.5) 1.8 (1.0–4.0) 2.1 (1.3–4.7) 0.135
Urinary ACR (mg/g) 6.9 (3.9–16.3) 6.9 (4.0–13.1) 6.5 (3.9–15.6) 0.419
Hypertension (%) 69.5 58.4 76.4 0.009
Systolic blood pressure (mmHg) 141.1617.9 140.0621.6 143.2620.6 0.123
Diastolic blood pressure (mmHg) 83.768.0 83.169.3 83.268.9 0.633
Creatinine (mg/dL) 1.060.2 1.060.2 1.060.1 0.442
Fibrinogen (mg/dL) 304.0664.5 293.1655.2 297.7657.0 0.917
Antithrombin III (%) 96.1611.7 98.2613.6 96.3613.2 0.621
D-dimer (mg/L) 0.7 (0.4–1.0) 0.5 (0.3–0.8) 0.5 (0.3–0.8) 0.231
Ferritin (mg/L) 108.96101.8 113.26120.1 138.06146.3 0.093
Homocystein (mmol/L) 12.566.1 12.066.4 12.366.0 0.931
Medication (%)
Statins 13.7 14.2 22.5 0.005
Aspirin 21.6 19.5 25.7 0.063
ACE inhibitors/ARBs 24.7 23.2 31.4 0.031
Beta-blockers 13.7 11.1 16.8 0.119
Calcium-channel blockers 14.7 7.9 17.3 0.104
Diuretics 24.2 16.8 25.7 0.084
Digitalis 5.3 5.3 6.3 0.152
Corticosteroids 0.5 0.5 0.5 0.554
Cumarine 2.1 6.3 4.2 0.418
Bisphosphonates 6.3 6.3 5.2 0.498
NSAR 12.6 6.8 11.5 0.793
Sex hormones
{ 5.3 6.7 13.6 0.041
Previous cardiovascular disease (%)
Ischemic stroke, myocardial infarction,
symptomatic peripheral artery disease and/or
any revascularisation procedure
10.5 10.5 11.5 0.637
ARBs, angiotensin-receptor blockers.
*Values presented are unadjusted means6SD, medians (IQR) or percentages.
{P values for the variables age and sex are from unadjusted analyses. All other P values are from analyses adjusted for age and sex.
{Analysis was confined to women only.
Factors to convert conventional units into SI units are as follows: glucose (mmol/L, 0.05551); cholestrerol (mmol/L, 0.0259); Triglycerides (mmol/L, 0.01129); Lipoprotein
(a) (mmol/L, 0.0357); Creatinine (mmol/L, 72.26); Fibrinogen (mmol/L, 0.0294); Ferritin (pmol/L, 2.247).
doi:10.1371/journal.pone.0000975.t001
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PLoS ONE | www.plosone.org 4 October 2007 | Issue 10 | e975Table 2. Association of demographic and life-style characteristics, vascular risk factors, laboratory parameters and medication with
EPC-CFUs number (n=542)
..................................................................................................................................................
CHARACTERISTIC* TERTILE GROUP FOR EPC NUMBER P Value for Trend
{
Low EPC colony number
(n=180)
Medium colony number
(n=181)
High colony number
(n=181)
EPC-CFUs (per 10
6 PBMNC)
Median 0 91 407
Range 0–23 24–202 203–1032
Demographic variables
Age (years) 68.969.6 68.369.6 68.969.3 0.850
Sex (%) 0.278
Men 43.9 46.4 49.7
Women 56.1 53.6 50.3
Life-style and vascular risk variables
Smoking (%) 12.8 14.9 14.4 0.811
Smoking (cigarettes per day) 1.564.7 1.664.7 1.664.8 0.992
Alcohol consumption (g/day) 17.7624.8 15.8623.7 20.5627.7 0.304
Physical activity (Sports score) 2.360.7 2.460.7 2.460.7 0.410
Diabetes mellitus (%) 11.1 8.8 11.0 0.812
Fasting glucose (mg/dL) 104.3623.8 102.4625.4 101.6617.5 0.248
Hba1c (%) 5.760.7 5.760.7 5.860.7 0.370
Waist (cm) 92.3611.5 91.0612.0 91.1613.1 0.237
Body-mass index (kg/m
2) 26.363.9 25.864.2 25.964.4 0.534
HDL cholestrerol (mg/dL) 64.2613.7 64.6613.6 63.6614.7 0.741
LDL cholestrerol (mg/dL) 138.3634.9 136.6631.3 134.1636.1 0.350
Triglycerides (mg/dL) 120 (91–163) 110 (93–155) 122 (92–158) 0.488
Lipoprotein(a) (mg/dL) 14.4 (4.5–36.7) 14.9 (6.3–45.7) 14.8 (5.8–41.3) 0.638
High-sensitivity CRP (mg/L) 1.9 (1.0–3.8) 1.8 (1.0–4.8) 2.1 (1.3–4.3) 0.242
Urinary ACR (mg/g) 6.6 (3.7–13.3) 7.1 (4.3–16.8) 6.5 (3.8–14.1) 0.821
Hypertension (%) 70.6 66.3 66.9 0.570
Systolic blood pressure (mmHg) 142.2619.2 141.3621.7 140.5619.5 0.482
Diastolic blood pressure (mmHg) 84.568.2 83.469.6 82.168.4 0.017
Creatinine (mg/dL) 1.060.2 1.060.2 1.060.2 0.789
Fibrinogen (mg/dL) 294.5663.5 299.3657.3 298.1656.5 0.554
Antithrombin III (%) 95.8611.9 96.9613.0 98.0613.3 0.049
D-dimer (mg/L) 0.6 (0.3–0.9) 0.5 (0.3–0.9) 0.5 (0.3–0.8) 0.128
Ferritin (mg/L) 121.46139.5 110.9696.6 127.76136.6 0.605
Homocystein (mmol/L) 12.766.0 11.966.3 12.366.4 0.746
Medication (%)
Statins 12.2 22.1 16.6 0.681
Aspirin 18.9 23.2 23.8 0.302
ACE inhibitors/ARBs 24.4 22.1 32.0 0.038
Beta-blockers 11.7 11.0 18.2 0.024
Calcium-channel blockers 11.7 12.7 13.3 0.657
Diuretics 20.0 20.4 24.3 0.189
Digitalis 2.2 5.5 7.7 0.018
Corticosteroids 0.0 0.6 1.1 0.180
Cumarine 3.3 4.4 5.0 0.495
Bisphosphonates 6.1 5.5 6.1 0.702
NSAR 9.4 11.0 10.5 0.761
Sex hormones
{ 8.9 7.2 8.8 0.908
Previous cardiovascular disease (%)
Ischemic stroke, myocardial infarction, symptomatic
peripheral artery disease and/or any revascularisation procedure
7.2 13.8 12.2 0.330
*Values presented are unadjusted means6SD, medians (IQR) or percentages.
{P values for the variables age and sex are from unadjusted analyses. All other P values are from analyses adjusted for age and sex.
{Analysis was confined to women only.
Factors to convert conventional units into SI units are as indicated in Table 1.
doi:10.1371/journal.pone.0000975.t002
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PLoS ONE | www.plosone.org 5 October 2007 | Issue 10 | e975numbers of EPCs by flow cytometry using either antibodies against
CD34 and KDR or CD133 were used in many previous studies.
However, double positive cells for DiI-Ac-LDL and Lectin in EPC
culture were counted as EPCs and used in the present study to
analyze the EPC numbers in circulation. The advantage for our
method is that the number of cultured EPCs not only reflect the
levels of circulating EPCs in humans, but also the proliferative
potential of EPC which is responsible for EPC function in
angiogenesis and vasculogenesis.
Another interesting observation in the current study is the
number of cultured EPCs, but not EPC-CFUs, was associated with
some cardiovascular risk factors, FRS and common carotid artery
atherosclerosis. Since the number of cultured EPCs include total
EPCs with lower or higher proliferative potential, whereas EPC-
CFU assay assesses a proportion of EPCs with higher proliferative
ability and clonogenic capacity. One possible explanation for such
difference between the number of cultured EPCs and EPC-CFU
assay is that they represent different functional subpopulation of
circulating EPCs. As controversy still exists over the exact
definition of circulating EPCs, comparison between studies using
different technique to assess EPC must be considered.
Paststudieswerehighlyconsistentinreportinginverseassociations
between EPC number and age[11], and postulated that this trend
renders elderly people prone to endothelial dysfunction and
cardiovascular diseases[11]. In the Bruneck cohort representative
for the general community a modest but significant decline in the
pool of circulating EPC emerged across the age range from 55 to
94 years (WEB Figure 2B). Moreover, we demonstrated for the first
time that the EPC number is significantly lower in (predominantly
postmenopausal) females than in males of equal age and higher
among subjects reporting regular (predominantly low-to-moderate)
alcohol consumption. In addition, subjects with statin, hormone
replacement and ACE inhibitor/angiotensin-receptor blocker ther-
apy exhibited higher EPC levels. This observation fits very well to
previous reports showing that these standard cardiovascular drugs
are capable of enhancing EPC numbers[34–36].
Several case-control studies and evaluations in patient series
indicated that the EPC number is inversely associated with
cardiovascular risk factors[4,12,13,28,37–40] giving raise to the
view that EPC are exhausted by the risk burden and unfavourable
life-style. However, the evidence available is far from consistent
and some studies even reported significant positive associations
between EPC and risk behaviors like smoking[8,9]. In our study
we revealed positive associations of EPC number with a number of
cardiovascular risk factors (table 1) and with the Framingham risk
score (FRS) (Figure 1A). The finding persisted after adjusting for
statin, hormone replacement and ACE inhibitor/angiotensin-
receptor blocker therapy. Speculatively, the positive association
between EPC number and the FRS in our study may reflect
a protective compensatory response to the individual vascular risk
burden. Discrepancy between the results of our current study and
previous various clinical studies may be explained by differences in
study design, composition of the study populations and variations
in risk factor levels. For instance, all the blood samples had been
taken at the exact same time (7:00 to 8:00 in the early morning
each day) and performed EPC analysis 2 hours later in our current
study. Most recently, our preliminary experimental data implicat-
ed that the blood sample collection time for EPC analysis is
particularly important. We observed that EPC number exhibited
diurnal variation with a 40–50% increase between 3pm and 10pm
and a 30–40% increase at 10pm compared with 8am. There are
also implications for studies involving serial sampling, such as
following myocardial infarction, where it is difficult to collect blood
samples at the same time, i.e. at a specific time point. Finally it
should be mentioned in this context that the current survey is the
largest available and the only one representative of the general
community. On the other hand the findings obtained to not
necessarily extend to extreme expressions of risk factors which
rarely occur in the general population.
Vascular repair is crucial to atherogenesis especially in its
advanced stages in which plaque fissuring and endothelial
denudation are common phenomena. Circulating EPCs have
been suggested to crucially contribute to vascular repair. Rauscher
and colleagues have explored the potential effects of EPC on vessel
pathology in ApoE deficient mice[41]. They found that old ApoE
deficient mice had suffered from exhaustive consumption of their
EPC and this had promoted development of atherosclerosis by
deficient vascular repair mechanism. Our study is the first to assess
an inverse association between EPC number and common carotid
Figure 1. Panel A illustrates the association between EPC number
(per 10
6 PBMNC) and the FRS (p=0.001). Panel B illustrates the
association between IMT and EPC number (per 10
6 PBMNC) (p=0.02).
doi:10.1371/journal.pone.0000975.g001
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PLoS ONE | www.plosone.org 6 October 2007 | Issue 10 | e975artery IMT (p=0.02) as well as the carotid artery atherosclerosis
score (p=0.059) both of which are surrogates for the severity of
systemic vessel pathology. However, the associations obtained
were only of moderate strength and did not extent to femoral
artery atherosclerosis. Previous studies had obtained solid associa-
tions between severity of coronary artery disease and EPC number
in symptomatic patients. Taken altogether these data indicate that
EPC may protect against atherogenesis but also that their
relevance increase with advancing vessel pathology and in
symptomatic cardiovascular disease.
There is solid evidence from experimental studies that pro-
genitor-related cytokines, such as VEGF[17], G-CSF[18,19],
SDF-1a[20,21], MMP-9[42,43] play a role in the EPC differen-
tiation, mobilization into circulation and homing. In the present
study we found a highly significant inverse relation between
plasma SDF-1a levels and both EPC number and EPC-CFU and
a significant positive relation between MMP-9 level and EPC
number (multivariate models). It was postulated that SDF-1a has
the ability to mediate homing of circulating EPC to tissues or
organs to be repaired or maintained, which may explain the lower
EPC pool in subjects with high SDF-1a. MMP-9 in turn was
implicated in the release of EPC from bone marrow into
blood[43]. There is a clear need for further investigating the
mechanisms by which SDF-1 and MMP-9 are engaged in EPC
mobilization and homing.
Counter expectation, in our study EPC number did not
significantly differ between subjects with and without a history of
previous cardiovascular disease. On interpreting these finding, how-
ever, it has to considered that most events had occurred already years
before conduction of these study and that patients had been subject to
extensive life-style modifications and drug therapy. Furthermore,
many patients had again entered a clinically inactive stage of vessel
disease.Incontrast,therecentintriguingstudiesrevealinglowerlevels
of EPCin subjects withcardiovascular diseasehad a focuson patients
with symptomatic coronary artery disease and acute coronary
syndromes. In these patients differences in EPC number and
functionality may be more pronounced because of an amplified
consumption or inadequate mobilization of circulating EPC.
In summary, our data implicated that the changes of the
number of EPCs are loosely associated with certain risk factors for
the cardiovascular disease and may not directly associated with the
disease development. In additional, one of our major finding in the
current study is unfavourable to the traditional view that the EPC
number is negatively affected by cardiovascular risk factors,
indicating that the role of EPC is more complex than assumed
previously. Our knowledge about the role of EPCs is far from
complete and will require further revisions. Compared to
previously data from case-control studies, our data also implicated
that the capacity to mobilze EPCs in acute disease is more
important than EPC basline levels.
Table 4. Association of cytokines with EPC colonY number (n=542)
..................................................................................................................................................
CHARACTERISTIC* TERTILE GROUP FOR EPC-CFU NUMBER P Value for Trend
{
Low EPC colony number
(n=180)
Medium EPC colony number
(n=181)
High EPC colony number
(n=181)
EPC-CFU (per 10
6 PBMNC)
Median 0 91 407
Range 0–23 24–202 203–1032
CYTOKINES
GCSF (pg/ml) 10.8 (5.1–18.7) 8.4 (5.1–13.5) 8.9 (4.2–17.4) 0.655
MMP9 (ng/ml) 63.8 (32.0–113.2) 61.6 (33.5–96.0) 68.1 (37.0–118.7) 0.605
SDF-1 (pg/ml) 2554 (2269–2922) 2553 (2292–2857) 2486 (2196–2769) 0.013
VEGF (pg/ml) 72.6 (35.6–145.1) 96.8 (29.3–163.8) 58.2 (24.2–135.6) 0.325
*Values presented are unadjusted means6SD or medians (IQR). Levels for GCSF, MMP9 and VEGF were available in 249, 528 and 356 subjects.
{P values are from analyses adjusted for age and sex.
doi:10.1371/journal.pone.0000975.t004
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Table 3. Association of cytokines levels with EPC number (n=571)
..................................................................................................................................................
CHARACTERISTIC* TERTILE GROUP FOR EPC NUMBER P Value for Trend
{
Low EPC level (n=190) Medium EPC level (n=190) High EPC level (n=191)
EPC number (per 10
6 PBMNC)
Median 127 560 1386
Range 17–295 296–859 860–4768
CYTOKINES
GCSF (pg/ml) 10.3 (4.2–18.3) 8.2 (3.6–14.5) 9.9 (5.0–17.8) 0.202
MMP9 (ng/ml) 57.8 (32.1–111.0) 66.3 (38.0–105.0) 71.4 (37.2–113.0) 0.295
SDF-1 (pg/ml) 2619 (2311–2956) 2469 (2218–2834) 2503 (2228–2767) 0.020
VEGF (pg/ml) 70.9 (30.0–138.8) 77.9 (34.5–162.9) 73.2 (27.5–158.9) 0.574
*Values presented are unadjusted means6SD or medians (IQR). Levels for GCSF, MMP9 and VEGF were available in 264, 556 and 374 subjects.
{P values are from analyses adjusted for age and sex.
doi:10.1371/journal.pone.0000975.t003
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